Evaluation of Long-Term Data With JAK Inhibitors

Video content above in prompted by the following:

• The JADE EXTEND study looked at abrocitinib use in patients who had previously taken dupilumab (Shi 2022). In your experience, does a patient’s positive response to one therapeutic suggest they will also be responsive to a different therapeutic? Similarly, do you find that nonresponders to one therapeutic also are nonresponders to other therapeutics?
• In patients who achieved an EASI-75 response with dupilumab, 83/92 (90.2%) achieved EASI-75 with 100 mg abrocitinib and 43/46 (93.5%) achieved EASI-75 with 200 mg abrocitinib after 12 weeks.
• In patients who did not achieve an EASI-75 response with dupilumab, 21/31 (67.7%) achieved EASI-75 with 100 mg abrocitinib and 16/20 (80.0%) achieved EASI-75 with 200 mg abrocitinib after 12 weeks.
• AEs included nasopharyngitis, nausea, acne, and headache.